Analyst Ratings For Global Blood Therapeutics (NASDAQ:GBT)
Today, Global Blood Therapeutics (NASDAQ:GBT) stock was downgraded by Morgan Stanley from Overweight to Equal Weight with a price target of $61.00.
Some recent analyst ratings include
- 3/21/2018-Morgan Stanley was Downgraded by analysts at Morgan Stanley from a “Overweight ” rating to a ” Equal Weight” rating. They now have a $61.00 price target on the stock.
- 3/14/2018-Wedbush Reiterated Rating of Outperform.
- 2/28/2018-William Blair Reiterated Rating of Buy.
- 2/13/2018-Janney Montgomery Scott initiated coverage with a Buy rating.
Recent Insider Trading Activity For Global Blood Therapeutics (NASDAQ:GBT)
Global Blood Therapeutics (NASDAQ:GBT) has insider ownership of 5.30% and institutional ownership of 85.40%.
- On 3/16/2018 Jung Choi, Insider, sold 3,000 with an average share price of $54.15 per share and the total transaction amounting to $162,450.00.
- On 3/5/2018 Lesley Ann Calhoun, Insider, sold 99 with an average share price of $60.35 per share and the total transaction amounting to $5,974.65.
- On 2/16/2018 Jung Choi, Insider, sold 3,000 with an average share price of $62.95 per share and the total transaction amounting to $188,850.00.
- On 2/1/2018 Peter Radovich, Insider, sold 812 with an average share price of $57.30 per share and the total transaction amounting to $46,527.60.
- On 1/23/2018 Peter Radovich, Insider, sold 30,000 with an average share price of $60.00 per share and the total transaction amounting to $1,800,000.00.
- On 1/17/2018 Jung Choi, Insider, sold 3,000 with an average share price of $52.85 per share and the total transaction amounting to $158,550.00.
- On 1/10/2018 Peter Radovich, Insider, sold 15,000 with an average share price of $50.00 per share and the total transaction amounting to $750,000.00.
Recent Trading Activity for Global Blood Therapeutics (NASDAQ:GBT)
Shares of Global Blood Therapeutics closed the previous trading session at with 0.0 shares trading hands.